Fintech PR
The Breakthrough Therapy Aiming To Solve The World’s Mental Health Crisis
FN Media Group Presents GlobalInvestmentDaily.com Market Commentary
LONDON, Sept. 19, 2023 /PRNewswire/ — Depression is costing the economy $1 trillion in lost production every single year. Yet, a classical compound that even the FDA has twice designated a “breakthrough therapy” is shaping up to potentially be the revolutionary treatment that big pharma has been waiting for. Mentioned in today’s commentary includes: Johnson & Johnson (NYSE: JNJ), AbbVie Inc. (NYSE: ABBV), Atai Life Sciences NV (NASDAQ: ATAI), Compass Pathways PLC (NASDAQ: CMPS), Mind Medicine (MindMed) Inc. (NASDAQ: MNMD).
Scientists say this “miracle compound” can help reset the brain and has huge implications for the treatment of people with…
- Depression and anxiety
- PTSD
- Addiction
- And many other disabling diseases…
But this is a game of patents, and with multi-billion-dollar IP at stake, Big Pharma certainly isn’t wasting any time…In fact, Johnson and Johnson (NYSE: JNJ) recently reported massive sales growth for its up-in-coming blockbuster drug for depression, SPRAVATO, which is the only FDA-approved psychedelic medicine on the market.
As reported on JNJ’s most recent earnings call, US & worldwide sales for SPRAVATO were up 93.2% & 98.6% y/y respectively, making it the fastest growing drug in its neuroscience portfolio (by far); and with US $170 million in Q2 2023 sales, J&J CEO, Joaquin Duato, went out of his way on the earnings call to dub SPRAVATO its next $1 billion-plus product…
Some of the core team behind the SPRAVATO IP recently joined a small but emerging NYSE American listed company on the leading edge of the next biotech breakthrough…
That company expects to report Phase 2 clinical data in just a few months, and it recently announced a game-changing agreement to acquire a key strategic asset . The company? Cybin
Cybin (NYSE:CYBN) (NEO:CYBN) is on the leading edge of transformational psychedelic therapeutics , developing novel and proprietary therapeutics to improve clinical outcomes and the mental health and wellbeing of patients. The emerging biopharmaceutical company already has clinical validation of the novel, proprietary CYB003 molecule, which demonstrates a rapid-acting and robust psychedelic profile, but at a low dose.
Cybin’s intellectual property portfolio encompasses several granted U.S. patents in support of its lead candidates – CYB003 and CYB004 – and over 50 pending patent applications across 6 patent families.
Two of the biggest drivers of value for Cybin in the near-term include Phase 2 topline efficacy data for CYB003, expected to be released in the fourth-quarter of this year, and the Phase 1 data for CYB004, also expected before the end of this year.
On August 28, Cybin announced an agreement to acquire Small Pharma Inc in an all-share transaction that creates an international clinical-stage leader in novel psychedelic therapeutics. The companies’ combined portfolios, at closing, will include two proprietary, advanced clinical programs in development for depression and anxiety disorders with demonstrated safety and efficacy.
De-Risking Safety and Efficacy: Near-Term Catalysts
Oppenheimer, which has initiated coverage on CYBN, is encouraged by the results so far, and believes the stock will have room to run further with new results expected before the end of the year.
The analysts expect the DMT acquisition to provide Cybin with “key synergies” as it “deepens focus on short treatment duration, expecting late 2023 readouts”.
Likewise, in an August 28, 2023 company update, H.C.Wainwright & Co. reiterated its “buy” rating on CYBN, with a price target of US $10.00 per share, after the recent Small Pharma acquisition, which it sees as strengthening Cybin’s position in short-acting psychedelics.
The acquisition also gives Cybin access to Small Pharma’s SPL026, “which has already demonstrated potential in MDD including rapid antidepressant effects that appear durable for six months based on datasets reported in January and April 2023, H.C.Wainwright noted.
The Proprietary Molecules That Are Changing Mental Health
“The molecular structure of psilocybin, a naturally occurring psychedelic compound found in ‘magic mushrooms,’ allows it to penetrate the central nervous system and the scientific and medical experts are just beginning to understand its effects on the brain and mind and its potential as therapeutics for mental illnesses,” according to Johns Hopkins Center for Psychedelic and Consciousness Research.
What makes Cybin’s pipeline so important to the new world of mental health is that from the start, it has set out to create novel and improved psilocybin molecules, while others in the space have been relying on generic materials that are not proprietary. This is a space where proprietary IP is absolutely essential, and Cybin now has 29 patents granted and 158 patents pending. That makes it the leader of intellectual property in this space.
Cybin has taken two molecules—DMT and psilocybin—and focused on the deuteration, which improves the molecules’ efficiency. In other words, it eases the path of the molecule into the brain, making it much faster and much more potent with a lower dose.
Lower doses mean more potency, and proprietary materials will have to lead this charge, giving the company with the most IP a huge advantage.
“Getting it out of the periphery and into the brain is now becoming much faster, without causing side effects,” says Drysdale. “If you get the molecules out of the blood stream and into the brain, you’re making it more efficient”.
There is an enormous need to address Major Depressive Disorder (MDD), the leading cause of disability due to mental illness.
Between 2010 and 2018, the cost of this illness in the U.S. alone soared 38%, affecting 17.5 million adults at a cost of a devastating $326 billion. That bill includes the direct medical costs of treating MDD, treating comorbidities, suicide-related costs and workplace productivity impacts. And that was five years ago. The costs continue to mount.
Another major unmet need in the mental health space is an effective treatment for anxiety disorders, which affect an estimated 18% of the U.S. population alone, or more than 300 million people around the world. Anxiety disorders are the sixth leading cause of disability in adolescents and young adults. Cybin’s CYB004 is hoping to address this need.
With the combined power of Cybin and Small Pharma and all the complex and proprietary IP that this merger brings together under a single umbrella, CYBN is positioned for big things in a space that desperately needs to cross the finish line on a new way to treat mental health.
With its IP catalogue, acquisition agreement, and near-term catalysts, Cybin’s (CYBN) small $75-million market cap appears to be far below its potential for the coming months and years. with its expected stage 2 clinical data reveal, this may set up Cybin for an exciting 2024.
A New Era of Healthcare Backed by Big Medicine
Johnson & Johnson (JNJ) is a multinational healthcare behemoth, with its fingers in a myriad of sectors ranging from pharmaceuticals to medical devices and consumer health products. Within the vast expanse of J&J’s portfolio, its pharmaceutical subsidiary, Janssen, ventured into the realm of mental health with the development of esketamine, marketed under the brand name Spravato. This nasal spray, which is a close relative of the anesthetic ketamine, received FDA approval for its use in treating treatment-resistant depression.
AbbVie (ABBV), a global powerhouse in the biopharmaceutical world, came into existence after its split from Abbott Laboratories in 2013. Since its inception, AbbVie has been laser-focused on developing treatments for a range of conditions, from rheumatoid arthritis to various forms of cancer.
The acquisition of Allergan by AbbVie brought with it a subtle yet significant pivot towards the psychedelic sector. Allergan, before its acquisition, had shown a keen interest in the potential of psychedelics, investing in research related to their use for mental health conditions.
Atai Life Sciences (ATAI), a clinical-stage biopharmaceutical company, emerged with a clear mission: to revolutionize the treatment of mental health disorders. Atai’s approach to mental health is both comprehensive and innovative. The company boasts a diverse pipeline of compounds, including a range of psychedelics, and has fostered collaborations with various companies to develop groundbreaking therapies.
Compass Pathways (CMPS) stands as a beacon in the realm of mental health care, with its pioneering research in the therapeutic use of psilocybin. Psilocybin, a psychedelic compound found in certain mushrooms, has been the focal point of Compass’s research endeavors.
The primary thrust of Compass’s research has been the potential application of psilocybin therapy for treatment-resistant depression. Through rigorous clinical trials and research initiatives, Compass Pathways seeks to legitimize and standardize the use of this compound in a therapeutic context
MindMed (MNMD) is a beacon of innovation in the neuro-pharmaceutical landscape. With its roots firmly planted in the exploration of psychedelic substances, the company seeks to unlock new treatment modalities for a range of mental health conditions. MindMed’s research portfolio is as diverse as it is promising. The company is actively exploring the therapeutic applications of substances like LSD, MDMA, DMT, and psilocybin. Each compound, with its unique properties, offers a potential avenue for addressing conditions like anxiety, depression, and addiction.
** IMPORTANT NOTICE AND DISCLAIMER — PLEASE READ CAREFULLY **
PAID ADVERTISEMENT. This article is a paid advertisement. FTB Capital and its owners, managers, employees, and assigns (collectively “the Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Cybin, Inc. (CYBN) to conduct investor awareness advertising and marketing. CYBN paid the Publisher to produce and disseminate this article and related banner ads for one hundred fifty thousand dollars. This compensation should be viewed as a major conflict with our ability to be unbiased.
Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price may likely occur.
This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser. This communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. This communication is based on information generally available to the public, and does not (to the Publisher’s knowledge, as confirmed by CYBN) contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher cannot guarantee the accuracy or completeness of the information.
FORWARD LOOKING STATEMENTS. This publication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. The Publisher notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the companies’ actual results of operations. Factors that could cause actual results to differ include, but are not limited to, government regulations concerning the products being developed by the company, the size and growth of the market for the companies’ products and services, the companies’ ability to fund its capital requirements in the near term and long term, pricing pressures, etc.
INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you acknowledge that you have read and understand this disclaimer, and further that to the greatest extent permitted under law, you release the Publisher, its affiliates, assigns and successors from any and all liability, damages, and injury from this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.
TERMS OF USE. By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here http://GlobalInvestmentDaily.com/Terms-of-Use. If you do not agree to the Terms of Use http://GlobalInvestmentDaily.com/Terms-of-Use, please contact GlobalInvestmentDaily.com to discontinue receiving future communications.
INTELLECTUAL PROPERTY. GlobalInvestmentDaily.com is the Publisher’s trademark. All other trademarks used in this communication are the property of their respective trademark holders. The Publisher is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks.
DISCLAIMER: GlobalInvestmentDaily.com is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with GlobalInvestmentDaily.com or any company mentioned herein. The commentary, views and opinions expressed in this release by GlobalInvestmentDaily.com are solely those of GlobalInvestmentDaily.com and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Contact Information:
Media Contact e-mail: [email protected] U.S. Phone: +1(954)345-0611
View original content:https://www.prnewswire.co.uk/news-releases/the-breakthrough-therapy-aiming-to-solve-the-worlds-mental-health-crisis-301931591.html
Fintech PR
Bitcoin Price Climbs 3% on US Shutdown and Yields Gloom, But Bitcoin Minetrix Raises $200,000 and Is the Real Winner
NEW YORK, Sept. 29, 2023 /PRNewswire/ — The Bitcoin price is defying macro gloom to put on a 3% gain as it recaptures $27,000, but it is yield-bearing Bitcoin Minetrix ($BTCMTX) that’s raised $200,000 and could be the biggest winner.
Bitcoin, after briefly slipping below $25k last month and struggling to make headway since peaking at 27,431 on September 19th, is threatening to retake that near-term high.
The move higher has been assisted by a confluence of factors and comes despite gathering storm clouds in the stock and bond markets.
Also, although equities had a green session on Thursday, it comes on the back of a negative week.
The S&P500 has fallen from 4,452 to 4,296, and the Nasdaq Composite slid 500 points, from 13,714 to 13,200. Meanwhile, US 10-Year Treasury yields continue their march higher, now at 4.66%.
And then there is US interest rates at 5.25-5.5% despite the Fed pause, making all risk assets look less attractive, plus a surging US dollar to factor in too.
Bitcoin teasing that it is a safe haven play after all?
Markets worry that US inflation will be stickier than hoped and that a soft landing could be for the birds. The weakening of the narrowly based bullish sentiment that has seen the Nasdaq make a 20% advance this year, has been evident for a few weeks now.
Fed chairman Jerome Powell’s speech on Thursday has done little to calm nerves.
The past few days have seen the gloom merchants come to the fore as a shutdown of the government looms and the real estate debt crisis deepens in China.
But the past few days have seen the gloom merchants come to the fore as a shutdown of the government looms and the real estate debt crisis deepens in China.
Against this backdrop, Bitcoin appears to be gaining in strength, although it is too early to say whether some safe-haven inflows are behind the improvement.
But when the ratings agencies start to talk about US debt losing its top-tier rating, fears of a recession mounting, the auto industry strike spreading, oil prices heading back to $100, and core inflation remaining as sticky as ever, the green shoots in the Bitcoin market are even more noticeable.
Add to the mix that good news for Coinbase – it needs some – came when it received permission to offer crypto futures trading to its non-US customers.
US competitor exchange Kraken announcing it planned to open its door to stock traders may have added to the positive vibes, although that development could be read as a sign of desperation on Kraken’s part as it scrabbles around for revenue.
What’s good for Bitcoin is good for crypto, and especially Bitcoin derivative coins like Bitcoin Minetrix
Bitcoin remains the bellwether of the crypto industry, so generally speaking, there tends to be a positive correlation between it and all other assets.
However, that correlation is magnified for so-called Bitcoin derivative and clone coins, of which Bitcoin Minetrix is the latest of the crop.
When Bitcoin does well, so do the likes of longstanding forked clones like Bitcoin Cash and Bitcoin SV, as well as new upstarts such as the HPOS10I (BITCOIN) meme coin, Bitcoin 2.0 and BTC20.
Bitcoin Minetrix is different from all those aforementioned coins though, because of its tangible connection with the Bitcoin network.
Its use case is to contribute to the hash power of the network by marshaling the collective might of retail investors – or stakers – to earn credits that can then be deployed in cloud mining Bitcoin.
Bitcoin Minetrix is the first stake-to-mine platform in crypto. There are certainly plenty of cloud-mining outfits out there, but none are fully decentralized. BTC Minetrix’s unique selling point is in effectively tokenizing cloud mining and harnessing the many advantages that it gives it over competitors.
https://twitter.com/bitcoinminetrix/status/1707002226898559469
Bitcoin Minetrix banishes fraudsters, makes mining Bitcoin cheaper and safer for all
With Bitcoin Minetrix there is no need to worry about fraud because everything is handled on-chain, and no cash changes hands.
Bear in mind, too, that Bitcoin Minetrix’s smart contract is fully audited by Coinsult – it passed with no major issues.
Smart contract automation makes withdrawal of funds super easy, as does earning credits and empowering individual stakers to decide how much mining they want to engage in and when.
Bitcoin Minetrix takes the complication and expense out of mining. You don’t need to understand how difficulty is calculated or how to keep your client software up to date.
What’s more, there’s no need to make a considerable capital outlay and be exposed to the risk of making a loss on your business undertaking.
Better than Bitcoin because Bitcoin Minetrix is a yield-bearing hedge where you can reinvest mining profits
But where does the Bitcoin and Macro interplay come into the picture, you might ask? Well, it comes down to bond yields.
Rising bond yields make non-yield-bearing assets less appealing. At the present time, lenders are demanding a higher return for buying US government debt. Among the biggest holders of US debt is China. Given the geopolitical uncertainties and tension, that relationship may not end well.
The price of bonds, which move inversely to yields, are going down because there are fewer buyers when inflation is high, cutting into fixed-income asset returns.
Now consider the economics of Bitcoin Minetrix. While Bitcoin has no yield-bearing property, Bitcoin Minetrix does.
However, in addition to token stakers earning a yield paid out of the tokens allocated for community rewards, they also earn credits that are then invested in cloud mining bitcoin.
https://twitter.com/bitcoinminetrix/status/1706639837304881263
Bitcoin Minetrix is in essence reinvesting dividends, the most powerful mechanism for wealth creation in finance.
Against the backdrop of rising yields, stocks, and in particular higher-risk growth stocks, become a riskier proposition, which is why the smart money looks for opportunities to lock in income streams.
Still, you don’t just want any old bond – Treasury Inflation Protected Securities (TIPS) are the ones to hold because they are index-linked.
But you could go one better and hold BTCMTX token and get an income stream plus capital appreciation and a built-in mechanism that reinvests your dividends.
Bitcoin Minetrix tokens do not have the indexation of TIPS, but arguably, they achieve pretty much the same thing via staking and cloud mining.
And if you just want a safe way to get into Bitcoin mining and all the rest is just cherry on the cake, then Bitcoin Minetrix really is the standout solution. Crypto analyst Michael Wrubel told his 300k YouTube subscribers pretty much exactly that in his latest video.
How to buy Bitcoin Minetrix ($BTCMTX)
Stake-to-mine innovator Bitcoin Minetrix is in phase 1 of its four-part roadmap. After the presale phase, the other three phases commence, encompassing development, launch, and mass adoption.
Although not scheduled until phase 2 and 3, talks with cloud providers and work on the stake-to-mine dashboard for app and desktop has already started.
To buy the $BTCMTX token you will need ETH, USDT, BNB or a bank card. If you plan to purchase with ETH you can start staking-to-earn straightaway.
Notes for editors
Website: https://bitcoinminetrix.com
Social Channels: Twitter | Discord | Telegram Community
Presale stages:
|
Presale Stage |
Token Price |
Percentage |
Amount of Tokens |
USD Value |
|
Phase 1 |
$0.01100000 |
10 % |
280,000,000 |
$3,080,000 |
|
Phase 2 |
$0.01110000 |
10 % |
280,000,000 |
$3,108,000 |
|
Phase 3 |
$0.01120000 |
10 % |
280,000,000 |
$3,136,000 |
|
Phase 4 |
$0.01130000 |
10 % |
280,000,000 |
$3,164,000 |
|
Phase 5 |
$0.01140000 |
10 % |
280,000,000 |
$3,192,000 |
|
Phase 6 |
$0.01150000 |
10 % |
280,000,000 |
$3,220,000 |
|
Phase 7 |
$0.01160000 |
10 % |
280,000,000 |
$3,248,000 |
|
Phase 8 |
$0.01170000 |
10 % |
280,000,000 |
$3,276,000 |
|
Phase 9 |
$0.01180000 |
10 % |
280,000,000 |
$3,304,000 |
|
Phase 10 |
$0.01190000 |
10 % |
280,000,000 |
$3,332,000 |
- Soft Cap – $15.6M – 1,400,000,000 Tokens
- Hard Cap – $32M
- Ethereum
- ERC-20
- $BTCMTX
- Starting Price – $0.011
- Presale Starting Date – 26/09/2023
- Minimum Buy – $10
Photo: https://mma.prnewswire.com/media/2235370/Bitcoin_Minetrix.jpg
View original content:https://www.prnewswire.co.uk/news-releases/bitcoin-price-climbs-3-on-us-shutdown-and-yields-gloom-but-bitcoin-minetrix-raises-200-000-and-is-the-real-winner-301943232.html
Fintech PR
Webb Unveils Tangle Network Testnet, Pioneering the Future of Private, Decentralized Applications
NEW YORK, Sept. 29, 2023 /PRNewswire/ — Today, Webb announced the launch of its much-anticipated Tangle Network Testnet, setting the stage for a new era of private and decentralized applications.
About Webb
Led by founder Drew Stone, Webb is the premier cross-chain zero-knowledge messaging layer, committed to revolutionizing blockchain privacy. Backed by industry giants like Polychain, Lemniscap, and Commonwealth Labs, Webb introduces a suite of tools aimed at advancing zero-knowledge (ZK) and multi-party computation (MPC) applications across multiple blockchains.
The Challenge and Our Solution
Blockchain networks today face significant hurdles: limited interoperability, scaling difficulties, centralized control, and privacy concerns. Webb’s Tangle Network, built on the powerful Substrate framework, is designed to tackle these challenges by offering a next-generation blockchain platform.
Why Tangle Network?
Our vision is to make it easier for developers to create secure, private zero-knowledge (ZK) and multi-party computation (MPC)-based decentralized applications. Tangle Network simplifies:
- Proof Generation: Delegate computational tasks to our validators.
- Trusted Setups: Tangle Network manages complex ceremonies for you.
- Secure Signing: Utilize our threshold signing for cross-chain operations.
By removing these barriers, we massively improve the time to launch for ZK and MPC-based decentralized applications.
Noteworthy Features
- Unparalleled speed, security, and scalability via Substrate.
- Decentralized control through Distributed Key Generation (DKG).
- Advanced protocols for zero-knowledge applications.
- Cross-chain compatibility with IBC and XCM.
- Easy migration of existing apps through Ethereum Virtual Machine (EVM) support.
- Smooth, forkless upgrades.
What’s Next?
The Testnet launch kicks off with an in-depth whitepaper, followed by a series of engagement events during the testnet phase. Our mainnet is scheduled for a Q1/Q2 2024 launch, featuring hackathons, workshops, and a targeted grant program to accelerate the adoption of privacy-focused applications.
Testnet Quick Links
- Whitepaper: Read here.
- Get Started: PolkadotApps for Tangle Network
- Documentation: docs.webb.tools
Get Involved
- Developers: Start building on Tangle today. Learn More
- Validators and Relayers: Help secure and maintain the network. Learn More
- Join the Community: Follow us on Twitter or join our Discord.
Contact Us
For media inquiries, partnerships, or more information, email us at [email protected]
View original content:https://www.prnewswire.co.uk/news-releases/webb-unveils-tangle-network-testnet-pioneering-the-future-of-private-decentralized-applications-301940846.html
Fintech PR
AMD Unveils Purpose-Built, FPGA-Based Accelerator for Ultra-Low Latency Electronic Trading
— New AMD Alveo fintech accelerator card provides trading firms and brokerages with breakthrough trade execution performance at nanosecond speed and AI-enabled trading strategies —
— Solution partners Alpha Data, Exegy and Hypertec add to growing ecosystem of ultra-low latency solutions for fintech market —
LONDON, Sept. 29, 2023 /PRNewswire/ — AMD (NASDAQ: AMD) today announced the AMD Alveo™ UL3524 accelerator card, a new fintech accelerator designed for ultra-low latency electronic trading applications. Already deployed by leading trading firms and enabling multiple solution partner offerings, the Alveo UL3524 provides proprietary traders, market makers, hedge funds, brokerages, and exchanges with a state-of-the-art FPGA platform for electronic trading at nanosecond (ns) speed.
The Alveo UL3524 delivers a 7X latency improvement over prior generation FPGA technology1, achieving less than 3ns FPGA transceiver latency2 for accelerated trade execution. Powered by a custom 16nm Virtex™ UltraScale™+ FPGA, it features a novel transceiver architecture with hardened, optimized network connectivity cores to achieve breakthrough performance. By combining hardware flexibility with ultra-low latency networking on a production platform, the Alveo UL3524 enables faster design closure and deployment compared to traditional FPGA alternatives.
“In ultra-low latency trading, a nanosecond can determine the difference between a profitable or losing trade,” said Hamid Salehi, director of product marketing at AMD. “The Alveo UL3524 accelerator card is powered by the lowest latency FPGA transceiver from AMD—purpose-built to give our fintech customers an unprecedented competitive advantage in financial markets.”
Hardware Flexibility and AI-Enabled Trading Strategies
Featuring 64 ultra-low latency transceivers, 780K LUTs of FPGA fabric, and 1,680 DSP slices of compute, the Alveo UL3254 is built to accelerate custom trading algorithms in hardware, where traders can tailor their design to evolving strategies and market conditions. Supported by traditional FPGA flows using Vivado™ Design Suite, the product comes with a suite of reference designs and performance benchmarks that allow FPGA designers to quickly explore key metrics and develop custom trading strategies to specification, backed by global support from AMD domain experts.
To simplify the increasing adoption of AI in the algorithmic trading market, AMD is providing developers with the open-sourced and community-supported FINN development framework. By using PyTorch and neural network quantization techniques, the FINN project enables developers to reduce the size of the AI models while retaining accuracy, compiling to hardware IP, and integrating the network model into the algorithm’s datapath for low latency performance. As an open-source initiative, the solution gives developers flexibility and accessibility to the latest advancements as the projects evolve.
Enabling a Growing Ecosystem of Ultra-Low Latency Fintech Solutions
The Alveo UL3524 and purpose-built FPGA technology are enabling strategic partners to build custom solutions and infrastructure for the fintech market. Currently available partner solutions include offerings from Alpha Data, Exegy, and Hypertec.
The AMD Virtex™ UltraScale+ VU2P FPGA powering the Alveo UL3524 accelerator card is enabling ultra-low latency appliances from Alpha Data.
“The new Virtex UltraScale+ FPGA from AMD brings a step change to ultra-low latency trading and networking,” said David Miller, managing director of Alpha Data. “We’ve developed the ADA-R9100 rack-mount appliance which allows customers to easily access the full potential of the new AMD FPGA device.”
Exegy, a provider of end-to-end, front-office trading solutions, is supporting the Alveo UL3524 card with its nxFramework, a software and hardware development environment tailored for creating and maintaining ultra-low latency FPGA applications within the financial industry.
“By combining the pioneering ultra-low latency FPGA technology from AMD with Exegy’s expertise in capital markets, we’re able to deliver a comprehensive solution that addresses the ever-increasing optimization needed to build the trading infrastructure of tomorrow,” said Olivier Cousin, director of FPGA solutions at Exegy.
Hypertec has optimized its ORION HF X410R-G6 High Frequency Server for the Alveo UL3524 with a custom cooling system to deploy in a 1U server form factor.
“The engineers at Hypertec specifically designed the HF X410R-G6 to extract the best out of the capabilities and speed of the Alveo UL3524 platform, catering our solution to the most demanding low-latency tasks,” said David Lim, director of product marketing, Hypertec.
The AMD Alveo UL3524 accelerator card is currently in production and shipping to global financial services customers.
Supporting Resources
- Learn more about the Alveo UL3524 accelerator card
- Become a fan of AMD on Facebook
- Follow AMD on Twitter
About AMD
For more than 50 years AMD has driven innovation in high-performance computing, graphics, and visualization technologies. Billions of people, leading Fortune 500 businesses, and cutting-edge scientific research institutions around the world rely on AMD technology daily to improve how they live, work, and play. AMD employees are focused on building leadership high-performance and adaptive products that push the boundaries of what is possible. For more information about how AMD is enabling today and inspiring tomorrow, visit the AMD (NASDAQ: AMD) website, blog, LinkedIn, and Twitter pages.
AMD, the AMD Arrow logo, Alveo, Virtex, Vivado and combinations thereof are trademarks of Advanced Micro Devices, Inc. Other names are for informational purposes only and may be trademarks of their respective owners.
1 Testing conducted by AMD Performance Labs as of 8/16/23 on the Alveo UL3524 accelerator card, using Vivado™ Design Suite 2023.1 and running on Vivado Lab (Hardware Manager) 2023.1. Based on the GTF Latency Benchmark Design configured to enable GTF transceivers in internal near-end loopback mode. GTF TX and RX clocks operate at same frequency of ~644MHz with a 180 degrees phase shift. GTF Latency Benchmark Design measures latency in hardware by latching value of a single free running counter. Latency is measured as the difference between when TX data is latched at the GTF transceiver and when TX data is latched at the GTF receiver prior to routing back into the FPGA fabric. Latency measurement does not include protocol overhead, protocol framing, programmable logic (PL) latency, TX PL interface setup time, RX PL interface clock-to-out, package flight time, and other sources of latency. Benchmark test was run 1,000 times with 250 frames per test. Cited measurement result is based on GTF transceiver “RAW Mode”, where PCS (physical medium attachment) of the transceiver passes data ‘as-is’ to FPGA fabric. Latency measurement is consistent across all test runs for this configuration. System manufacturers may vary configurations, yielding different results. ALV-10
2 Based on simulation comparison between Virtex UltraScale+ GTY transceivers and ultra-low latency GTF transceivers.
View original content:https://www.prnewswire.co.uk/news-releases/amd-unveils-purpose-built-fpga-based-accelerator-for-ultra-low-latency-electronic-trading-301943169.html
-
Fintech PR2 weeks ago
2023 Asian Green and Low-Carbon Development Roundtable successfully held
-
Fintech PR2 weeks agoAon Joins International Emissions Trading Association as First Member with Risk Capital Capabilities
-
Fintech PR2 weeks agoWearable Devices and IoT Revolutionize Healthcare Monitoring and Weight Management
-
Fintech PR2 weeks agoMYEG PARTNERS CHINA’S BEITOU IT INNOVATION TO SHOWCASE DIGITAL IDENTITY CREDENTIALS SERVICE ON THE ZETRIX BLOCKCHAIN
-
Fintech PR2 weeks agoTom Fitzpatrick Joins R.J. O’Brien as Managing Director, Global Markets Insights
-
Fintech PR2 weeks agoStockings shift toward subscriptions this holiday season for UK shoppers, according to Recurly research
-
Fintech PR2 weeks agoMAX Exchange and Bitget announce strategic partnership, marking MAX Token’s debut on an international exchange
-
Fintech PR2 weeks agoIngenico and Diggecard announce a comprehensive gift card solution for acquirers using PPaaS, Ingenico’s Payments Platform as a Service